Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome
Jul292019

Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome

July 29, 2019
Jul172019

Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer’s Association International Conference (AAIC)

July 17, 2019
Jun252019

Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome

June 25, 2019
Jun62019

Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome (AVATAR)

June 6, 2019
May82019

Rett Syndrome Association of Australia and Anavex Life Sciences Announce Initiation of the Phase 2 AVATAR Clinical Study in Patients with Rett Syndrome

May 8, 2019
May82019

Anavex Life Sciences Reports Fiscal 2019 Second Quarter Financial Results And Provides Clinical Study Updates

May 8, 2019
May62019

Anavex Life Sciences to Announce Fiscal 2019 Second Quarter Financial Results on Wednesday May 8th, 2019

May 6, 2019
Apr52019

Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference

April 5, 2019
Mar282019

Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer’s Disease at the American Society for Experimental Neurotherapeutics – ASENT 2019 Annual Meeting

March 28, 2019
Mar182019

Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome in the U.S.

March 18, 2019
Mar132019

Anavex Life Sciences to Present at the 31st Annual ROTH Conference 2019

March 13, 2019
Mar112019

Anavex Life Sciences Reaches 50% Enrollment Threshold in ANAVEX®2-73 Parkinson’s Disease Dementia (PDD) Phase 2 Study Ahead of Schedule

March 11, 2019
1
2
…34567…
891011121314151617181920212223242526272829303132333435363738394041
42

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top